Macquarie Group
ADMA icon

Macquarie Group’s ADMA Biologics ADMA Stock Holding History

Macquarie Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,395,099
Closed -$20.5M – 856
2025
Q3 		$20.5M Sell
1,395,099
-179,442
-11% -$3.08M 0.02% 657
2025
Q2 		$28.7M Buy
1,574,541
+128,151
+9% +$2.61M 0.04% 563
2025
Q1 		$28.7M Buy
1,446,390
+431,701
+43% +$7.47M 0.04% 556
2024
Q4 		$17.4M Sell
1,014,689
-123,634
-11% -$2.33M 0.02% 680
2024
Q3 		$22.8M Buy
1,138,323
+955,990
+524% +$14.9M 0.02% 636
2024
Q2 		$2.04M Sell
182,333
-66,281
-27% -$556K ﹤0.01% 1217
2024
Q1 		$1.64M Sell
248,614
-25,622
-9% -$140K ﹤0.01% 1279
2023
Q4 		$1.24M Buy
+274,236
New +$1.01M ﹤0.01% 1336

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Macquarie Group's ADMA Position: Q4 2025 in Review

Macquarie Group sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 1,395,099 shares — an estimated $20.5M sold.

Macquarie Group first reported a position in ADMA in Q4 2023 and held it in 8 quarters. The position peaked at $28.7M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Macquarie Group reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 1,395,099 ADMA Biologics shares in Q4 2025, an estimated $20.5M.
  • Macquarie Group first reported a position in ADMA Biologics in Q4 2023 and held it in 8 quarters.
  • Macquarie Group's ADMA Biologics position peaked at $28.7M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.